Investor Presentation Q1 2023

49 Investor presentation First three months of 2023 The full ONWARDS programme with once-weekly insulin Icodec completed in 2022 1 2 4 5 Basal initiation 52 weeks 1,085 ONWARDS 3 Basal initiation Basal switch Basal initiation Basal/Bolus 52 weeks² (Full trial: 78 weeks) 26 weeks 26 weeks 26 weeks 526 588 582 8.1% 8.5% 8.3% 8.9% Duration Participants 984 Baseline Change in HbA1c (%) 8.5% 6 Basal/Bolus 26 weeks² (Full trial: 52 weeks) 583 7.6% -0.47% -0.51% Hypo- glycaemia event rates¹ -0.71% -0.93%* -1.35% -1.55%* 0.30 0.16 0.73 0.27 -1.16% -1.18% -1.36% -1.31% -1.57%* -1.68%* 0.31 0.15 5.64 5.62 0.19 0.14 19.93 10.37* Novo NordiskⓇ In people with type 2 diabetes: No statistical difference in estimated hypoglycaemia events Once-weekly insulin icodec Once-daily insulin glargine U100 Once-daily insulin degludec In people with type 1 Once-daily basal insulin diabetes * Statistically significant in terms of superiority. 'Severe or clinically significant hypoglycaemia events (blood glucose <3 mmol/L) per patient year 2 Duration refers to trial main phase. T1D: Type 1 diabetes; T2D: Type 2 diabetes ONWARDS 1: QW insulin icodec vs QD insulin glargine U100 both with non-insulin anti-diabetic treatment in insulin-naïve people with T2D; ONWARDS 2: QW insulin icodec vs QD insulin degludec in people with T2D switching from a QD insulin; ONWARDS 3: QW insulin icodec vs QD insulin degludec in insulin-naïve people with T2D; ONWARDS 4: QW insulin icodec vs QD insulin degludec both with mealtime insulin in people with T2D treated with basal and bolus insulin; ONWARDS 5: QW insulin icodec vs QD basal insulin with an app providing dosing recommendation in insulin-naïve people with T2D; ONWARDS 6: QW insulin icodec vs QD insulin degludec both with mealtime insulin in people with T1D

View entire presentation